All In Biotech

Drug Trial Radar · NCT02689999

The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity

Last checked: Nov 20, 2026Latest source record: Aug 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Feb 2016

Primary completion

May 2017

Study completion Aug 2017

Sponsor

Lead sponsor
Neutec Ar-Ge San ve Tic A.ŞIndustry
Sponsor type
Industry
First posted
Feb 24, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is planned to investigate the effect of dexrabeprazole on gastric acid primarily, and then gastroesophageal reflux disease (GERD) symptoms, intraesophageal acidity (reflux) and impedance kinetics.

Conditions

  • Gastroesophageal Reflux Disease (GERD)

Interventions

  • Dexrabeprazole 10 mg Enteric-Coated TabletsDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. - The percent of pH < 4 duration of 24-hour intragastric acidity and intraesophageal acidity after seven-days treatment.Time frame: One week
  2. - The area under curve (AUC) of pH < 4 duration of 24-hour intragastric acidity and intraesophageal acidity after seven-days treatment.Time frame: One week

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Ankara University Gastroenterology Department

    Ankara, Turkey (Türkiye)

  • On Dokuz Mayıs University Gastroenterology Department

    Samsun, Turkey (Türkiye)

  • Ege University Gastroenterology Department

    Izmir, Bornova, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.